Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

[1] Sokka T(1999)Work disability in rheumatoid arthritis 10 years after the diagnosis J Rheumatol. 26 1681-1685

[2] Kautiainen H(2001)The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol. 137 280-284

[3] Möttönen T(2012)Impact of psoriatic arthritis on the patient: through the lens of the WHO international classification of functioning, health, and disability Curr Rheumatol Rep. 14 369-374

[4] Hannonen P(2013)The role of biosimilars in the treatment of rheumatic diseases Ann Rheum Dis. 72 322-328

[5] Krueger G(2015)Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis RMD Open. 1 e000019-1632

[6] Koo J(2010)Patient reported outcomes: looking beyond the label claim Health Qual Life Outcomes. 8 89-27

[7] Lebwohl M(2003)Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy JAMA 290 1624-18

[8] Menter A(2011)Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice Scand J Rheumatol Suppl. 125 23-926

[9] Stern RS(2016)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs update Ann Rheum Dis. 2017 1-1431

[10] Rolstad T(2017)Is there a reason for concern or is it just hype? A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars Expert Opin Biol Ther. 17 915-9

[1] Sokka T(1999)Work disability in rheumatoid arthritis 10 years after the diagnosis J Rheumatol. 26 1681-1685

[2] Kautiainen H(2001)The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol. 137 280-284

[3] Möttönen T(2012)Impact of psoriatic arthritis on the patient: through the lens of the WHO international classification of functioning, health, and disability Curr Rheumatol Rep. 14 369-374

[4] Hannonen P(2013)The role of biosimilars in the treatment of rheumatic diseases Ann Rheum Dis. 72 322-328

[5] Krueger G(2015)Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis RMD Open. 1 e000019-1632

[6] Koo J(2010)Patient reported outcomes: looking beyond the label claim Health Qual Life Outcomes. 8 89-27

[7] Lebwohl M(2003)Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy JAMA 290 1624-18

[8] Menter A(2011)Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice Scand J Rheumatol Suppl. 125 23-926

[9] Stern RS(2016)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs update Ann Rheum Dis. 2017 1-1431

[10] Rolstad T(2017)Is there a reason for concern or is it just hype? A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars Expert Opin Biol Ther. 17 915-9